Nirsevimab-alip

(Beyfortus®)

Nirsevimab-alip

Drug updated on 11/17/2023

Dosage FormInjection (intramuscular; 50 mg/0.5 mL in a single-dose pre-filled syringe)
Drug ClassRespiratory syncytial virus (RSV) F protein-directed fusion inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Product Monograph / Prescribing Information

Document TitleYearSource
Beyfortus (nirsevimab-alip) Prescribing Information.2023Sanofi Pasteur, Inc., Swiftwater, PA 18370 USA

Systematic Reviews / Meta-Analyses